SCHEMBL1274091

SCHEMBL1274091

O=[C]COc1ccc(CO)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.45
PPARA Q07869 3/20 0.42
PPARG P37231 2/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
CYSLTR1 Q9Y271 1/20 0.39
EGLN1 Q9GZT9 1/20 0.39
GSTP1 P09211 1/20 0.38
PTGER4 P35408 1/20 0.37
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA4 P22748 2/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2170360 0.84 CA12 (0.42) PPARAMEN1KMT2AGSTP1CA12
SCHEMBL15873588 0.80 HRH3 (0.46) LTA4HPPARAPPARGMEN1KMT2A
SCHEMBL634910 0.79 LTA4H (0.45) LTA4HPPARAPPARGMEN1KMT2A
SCHEMBL11012248 0.79 MAOB (0.48) HRH3
SCHEMBL3677826 0.79 GSTP1 (0.55) LTA4HMEN1KMT2AHRH3CYSLTR1
SCHEMBL23091403 0.79 IDO1 (0.48) LTA4HPPARAGSTP1CA12CA1
SCHEMBL8012112 0.79 FFAR1 (0.50) CA2TSHR
SCHEMBL2641227 0.78 LTA4H (0.47) LTA4HMEN1KMT2APTPN1
SCHEMBL7773816 0.77 TSHR (0.53) PPARAPPARGCYSLTR1TSHR
SCHEMBL26962314 0.76 ADAM17 (0.47) LTA4HPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12024537-B2 Compositions and methods for chemical synthesis SEDERMA (FR) 2024-07-02 US claimed
EP-3802554-B1 METHOD FOR SOLUTION-PHASE PEPTIDE SYNTHESIS AND PROTECTING STRATEGIES THEREFORE SEDERMA SA (FR) 2023-12-13 EP claimed
EP-4251632-A1 COMPOSITIONS AND METHODS FOR CHEMICAL SYNTHESIS Sederma (FR) 2023-10-04 EP claimed
WO-2022115825-A1 COMPOSITIONS AND METHODS FOR CHEMICAL SYNTHESIS GAP PEPTIDES, LLC (US) 2022-06-02 WO claimed
US-20210170037-A1 BRANCHED SUGAR ALCOHOL-BASED COMPOUNDS, AND COMPOSITIONS AND METHODS THEREOF CELLMOSAIC INC (US) 2021-06-10 US claimed
EP-3802554-A1 METHOD FOR SOLUTION-PHASE PEPTIDE SYNTHESIS AND PROTECTING STRATEGIES THEREFORE Gap Peptides LLC (US) 2021-04-14 EP claimed
CN-112584871-A Branched sugar alcohol-based compounds and compositions and methods thereof 希默赛生物技术公司 2021-03-30 CN claimed
US-20210079036-A1 COMPOSITIONS AND METHODS FOR CHEMICAL SYNTHESIS GAP PEPTIDES LLC (US) 2021-03-18 US claimed
EP-1945798-B1 METHOD FOR DETERMINING THE CLEAVABILITY OF SUBSTRATES FORSCHUNGSZENTRUM BORSTEL (DE) 2013-05-22 EP claimed
US-20090258381-A1 Methods for Determining the Cleavability of Substrates FORSCHUNGSZENTRUM BORSTEL (DE) 2009-10-15 US claimed
EP-1945798-A2 METHODS FOR DETERMINING THE CLEAVABILITY OF SUBSTRATES Forschungszentrum Borstel (DE) 2008-07-23 EP claimed
WO-2007051605-A2 METHODS FOR DETERMINING THE CLEAVABILITY OF SUBSTRATES FORSCHUNGSZENTRUM BORSTEL (DE) 2007-05-10 WO claimed
US-20050130228-A1 Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form H. LUNDBECK A/S (DK) 2005-06-16 US claimed
WO-2004050686-A2 PROCESS AND SUPPORTS FOR SYNTHESIS OF PEPTIDES COMPRISING A THIOESTER OR THIOACID AVECIA LIMITED (GB) 2004-06-17 WO claimed
US-20030138847-A1 Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form H. LUNDBECK A/S (DK) 2003-07-24 US claimed
EP-1268050-A2 DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM H. Lundbeck A/S (DK) 2003-01-02 EP claimed
WO-2001068598-A2 DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM H. LUNDBECK A/S (DK) 2001-09-20 WO claimed
US-12024537-B2 Compositions and methods for chemical synthesis SEDERMA (FR) 2024-07-02 US disclosed
EP-0277561-B1 NEW ARGININE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF AND ITS USE IN PEPTIDE SYNTHESIS ENIRICERCHE S.p.A. (IT) 1992-04-15 EP disclosed
EP-0277561-A1 New arginine derivative, process for the preparation thereof and its use in peptide synthesis ENIRICERCHE S.p.A. (IT) 1988-08-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170037-A1 BRANCHED SUGAR ALCOHOL-BASED COMPOUNDS, AND COMPOSITIONS AND METHODS THEREOF SIGLEC7, CD44, SIGLEC9 LTA4H 3304/4885PPARA 1864/4885PPARG 2078/4885
US-20090258381-A1 Methods for Determining the Cleavability of Substrates CTSF, ADAM17, ADAM10 LTA4H 824/4885PPARA 4824/4885PPARG 4849/4885
US-12024537-B2 Compositions and methods for chemical synthesis NGLY1, DNPEP, HM13 LTA4H 1151/4885PPARA 4556/4885PPARG 4374/4885
US-20210079036-A1 COMPOSITIONS AND METHODS FOR CHEMICAL SYNTHESIS NGLY1, DNPEP, HM13 LTA4H 1151/4885PPARA 4556/4885PPARG 4374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.